Research programme: factor X/Xa variants - Catalyst BiosciencesAlternative Names: CB FXa
Latest Information Update: 06 Jul 2015
At a glance
- Originator Catalyst Biosciences
- Class Blood coagulation factors
- Mechanism of Action Blood coagulation factor replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haemophilia; Haemorrhage